Biologic Drugs With Established Pharmaceutical Class: CD38-directed Cytolytic Antibody
✉ Email this page to a colleague
Biologic Drugs With Established Pharmaceutical Class: CD38-directed Cytolytic Antibody
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | DARZALEX | daratumumab | Injection | 761036 | 2015-11-16 | ⤷ Start Trial | ⤷ Start Trial |
| Janssen Biotech, Inc. | DARZALEX | daratumumab | Injection | 761036 | 2015-11-16 | 7,829,673 | ⤷ Start Trial |
| Janssen Biotech, Inc. | DARZALEX | daratumumab | Injection | 761036 | 2015-11-16 | 9,040,050 | ⤷ Start Trial |
| Janssen Biotech, Inc. | DARZALEX | daratumumab | Injection | 761036 | 2015-11-16 | 9,187,565 | ⤷ Start Trial |
| Janssen Biotech, Inc. | DARZALEX | daratumumab | Injection | 761036 | 2015-11-16 | 78,296,737,829,673 | ⤷ Start Trial |
| Janssen Biotech, Inc. | DARZALEX | daratumumab | Injection | 761036 | 2015-11-16 | 90,400,509,040,050 | ⤷ Start Trial |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Patent Expiration |
